Showing results (81-90 of 109) with videos related to
Sort By:
Pageof 11
Nature|March 19, 2026
Thymic health and immunotherapy outcomes in patients with cancerSimon Bernatz, Vasco Prudente, Suraj Pai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.Cancer Immunology, Immunotherapy : CII|October 2, 2024
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapyAndrea De Giglio, Alessandro Leonetti, Francesca Comito, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 22, 2025
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping MutationsFederica Pecci, Prashasti Agrawal, Jessica S Ross, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLCSeshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.JTO Clinical and Research Reports|January 13, 2025
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated TumorsAlissa J Cooper, Andrea Arfe, Biagio Ricciuti, et al.JAMA Oncology|December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung CancerMehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung CancerLaura Cipriani, Davide Mascolo, Stefano Scalera, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLCJoao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.Pageof 11